Urine Biomarkers for the Detection of Urothelial Carcinoma

Posted by Siamak Daneshmand, MD | Jul 2021

Siamak Daneshmand, MD, presented “Urine Biomarkers for the Detection of Urothelial Carcinoma” during the International Bladder Cancer Update 2021 virtual conference in April 2021.

How to cite: Daneshmand, Siamak. “Urine Biomarkers for the Detection of Urothelial Carcinoma” April 2021. Accessed Apr 2024. https://grandroundsinurology.com/urine-biomarkers-for-the-detection-of-urothelial-carcinoma/

Urine Biomarkers for the Detection of Urothelial Carcinoma – Summary:

Siamak Daneshmand, MD, Associate Professor of Urology and Director of Clinical Research at the University of Southern California, discusses the ability of urinary markers to rule bladder cancer in or out and to decrease the frequency of and need for cystoscopy and cytology. He begins by stating that cystoscopy misses carcinoma in situ (CIS), upper tract tumors, and is invasive. He also notes that cytology is inconsistent, missing about 20% of high-grade disease and providing false negatives for low-grade disease. Dr. Daneshmand then considers the potential biomarkers for detection.. He reviews a study of fluorescence in situ hybridization (FISH) showing its utility in risk stratifying patients entering clinical trials who fail to respond to induction therapy, and then looks at a study of the efficacy and safety of blue light flexible cystoscopy that showed a high positive predictive value but a lack of information on patient disease. Dr. Daneshmand then summarizes the current FDA-approved urinary biomarkers and the NCCN guidelines on cystoscopy, upper tract imaging, abdominal and pelvic imaging, and urine tests before explaining that biomarkers shouldn’t be used for every patient. Dr. Daneshmand considers studies that support the use of Cxbladder, Bladder EpiCheck, Bladder CARE™, and Decipher Bladder. He concludes with reviews of a study on precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and of a study on the clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma.

About the International Bladder Cancer Update 2021 virtual conference:
The International Bladder Cancer Update (IBCU) is a CME conference focused on the diagnosis and treatment of bladder cancer. The conference offers medical professionals an opportunity to listen to updates from, and interact with, expert international faculty to improve knowledge and determine best treatment practices to improve patient outcomes. IBCU encompasses expert lectures, interactive discussions, a panel roundtable, debates, and case presentations. It is physician-led, multi-supported, and designed for urologists, urologic oncologists, and other healthcare professionals involved in the treatment of bladder cancer.

About The Author

Siamak Daneshmand, MD

Siamak Daneshmand, MD, is Professor of Urology and Medicine (Oncology) with Clinical Scholar designation and serves as Director of Urologic Oncology, as well as the Urologic Oncology (SUO) Fellowship Director at the University of Southern California (USC) in Los Angeles. His main clinical interests include bladder cancer, testicular cancer, and advanced kidney cancer. He is a leading authority in the management of complex germ cell tumors and nerve-sparing retroperitoneal lymph node dissection (RPLND) following chemotherapy for advanced testicular cancer and is one of the highest volume surgeons for this disease in the country. His main research interests focus on the use of pathways to improve perioperative outcomes following radical cystectomy and post-chemo RPLND, use of serum and molecular markers and new technologies in diagnosis and management of bladder and testicular cancers, as well as functional outcomes following orthotopic urinary diversion. He serves on the American Urological Association (AUA) guidelines panel for non-muscle invasive bladder cancer, as well as the AUA guidelines panel for testicular cancer. He currently serves as the chair of bladder section of the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), is on the scientific steering committee of several bladder cancer clinical trials, and has led over a dozen clinical trials in bladder cancer and a pivotal trial in testicular cancer (SEMS). He is currently secretary of the Western Section of the AUA. He is a member of Alpha Omega Alpha medical honor society and has been designated one of the “America’s Top Cancer Doctors” for the past 12 consecutive years. He has been a career leader in academic investigations in bladder cancer and germ cell tumors and was recently appointed as the chair of the SWOG Cancer Research Network local bladder committee. He has been a visiting professor at more than 25 institutions around the world. He has presented over 500 abstracts at scientific meetings and has authored over 375 peer-reviewed articles, reviews, and book chapters. Dr. Daneshmand earned his medical degree at the University of California, Davis, and completed his residency at the University of Southern California, followed by a two-year fellowship in Urologic Oncology at the University of Southern California’s Norris Comprehensive Cancer Center.

Join the GRU Community

- Why Join? -

Share This

Chat with usLiveChat